Arsalan Arif

We were broke when we launched Endpoints on this day ten years ago. Not startup broke, with a seed round and runway. Actually broke. No benefactors, no backup plan. Nobody to answer to because nobody had written a check. So we did something every advisor told us not to: split ownership 50/50. That type of dynamic usually ends badly for founders. But it was the only way that made sense for us. And that bond turned out to be the single most valuable asset we had.

Today we’re launching Endpoints Signal — a new biopharma intelligence platform that gives Endpoints News subscribers a trusted read on where biopharma is headed, and why. Signal is powered by surveying the Endpoints readership — the largest, most influential group of biopharma pros in the world. Signal’s flagship product is the Biopharma Sentiment Index, a new landmark quarterly gauge of the mood across biopharma.

Endpoints News is moving to a new website domain on June 1, 2025. The front door is now at: https://endpoints.news The goal is a seamless transition to a URL that is an exact match to our brand. If you have any saved bookmarks, we kindly ask that you swap endpts.com for endpoints.news — everything works the same. Nothing else changes. We plan to redirect legacy endpts.com traffic for the foreseeable future to minimize service disruptions. Why the change?